Impact of particulate matter 2.5 exposure on severity of pediatric chronic rhinitis: A prospective cohort study
Pediatric Allergy and Immunology · 2026
DOI: 10.1111/pai.70493 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Rinrada Naka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Particulate Matter, Rhinitis, Environmental Exposure, Air Pollutants. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Fund, Faculty of Medicine Ramathibodi Hospital, Mahidol University.
Abstract (Originalsprache)
Background
Particulate matter with a diameter of ≤2.5 micrometers (PM 2.5 ) is associated with respiratory and allergic diseases. However, the longitudinal impact on pediatric rhinitis control remains limited.
Objectives
To determine the association between PM 2.5 exposure and symptom control in pediatric patients with chronic rhinitis.
Methods
This prospective longitudinal study (July 2024–August 2025) followed children with chronic rhinitis in the Bangkok Metropolitan Region. Rhinitis symptom severity was assessed weekly using a visual analog scale (VAS), with covariates such as medication use and concurrent respiratory infections. A 1‐week average PM 2.5 concentration preceding VAS assessment (via Inverse Distance Weighting interpolation) was estimated. Associations between PM 2.5 exposure and VAS were analyzed using multivariable mixed‐effects and fixed‐effects linear regression models. Additional analyses were stratified by aeroallergen sensitization status (allergic rhinitis versus nonallergic rhinitis).
Results
Among 146 children followed for a median of 52 weeks, higher PM 2.5 exposure (per 10 μg/m 3 ) was consistently associated with increased VAS ( β coefficient; 95% confidence interval = 0.260; 0.215–0.306, p < .001). Wet season, concurrent respiratory infections, and medication use were also associated with increased VAS. These associations were observed in both allergic rhinitis and nonallergic rhinitis.
Conclusion
Higher short‐term ambient PM 2.5 exposure was associated with greater rhinitis symptom severity in children with chronic rhinitis. These findings support consideration of ambient air pollution as an environmental factor in pediatric rhinitis management. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Geo-Informatics and Space Technology Development Agency, Chonburi, Thailand.
- Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Rinrada Naka, Wiparat Manuyakorn
Förderung
- Research Fund, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Zitieren
APA
Naka, R., Sinitkul, R., Nithirochananont, U., Kanchongkittiphon, W., Kiewngam, P., Jotikasthira, W., Sawatchai, A., Suppasilp, C., & Manuyakorn, W. (2026). Impact of particulate matter 2.5 exposure on severity of pediatric chronic rhinitis: A prospective cohort study. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70493
Vancouver
Naka R, Sinitkul R, Nithirochananont U, Kanchongkittiphon W, Kiewngam P, Jotikasthira W, et al. Impact of particulate matter 2.5 exposure on severity of pediatric chronic rhinitis: A prospective cohort study. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70493
BibTeX
@article{Naka2026,
author = {Naka, Rinrada and Sinitkul, Ratchaneewan and Nithirochananont, Ussanai and Kanchongkittiphon, Watcharoot and Kiewngam, Potjanee and Jotikasthira, Wanlapa and Sawatchai, Adithep and Suppasilp, Chaiyawat and Manuyakorn, Wiparat},
title = {Impact of particulate matter 2.5 exposure on severity of pediatric chronic rhinitis: A prospective cohort study},
journal = {Pediatric Allergy and Immunology},
year = {2026},
doi = {10.1111/pai.70493}
}
EUVIMED